Daridorexant is approved to treat insomnia in adults who have difficulty with sleep onset or maintenance.
On January 10, 2022, the FDA approved daridorexant (Quviviq; Idorsia) for the treatment of adults with insomnia who have difficulty with sleep onset and/or maintenance. Daridorexant is expected to be available in May 2022, after scheduling by the Drug Enforcement Administration.1
What is Daridorexant and How Does It Work?
Daridorexant is an orexin receptor antagonist. It is thought to work by binding to and inhibiting orexin receptors. The orexin neuropeptide signaling system is associated with wakefulness. By blocking the binding of wake-promoting neuropeptides orexin A and B to their receptors, daridorexant is thought to suppress wake drive.2
What is the Dosage?
Daridorexant is available in 25 mg and 50 mg tablets. Dosing is 25 mg to 50 mg by mouth, no more than once per night. The patient should take daridorexant in the 30 minutes before going to sleep, with at least 7 hours remaining to sleep.2
Counseling pearl: Daridorexant takes longer to work if it is taken with—or shortly—after a meal.2
Daridorexant should not be used in combination with strong CYP3A4 inhibitors. When taken with a moderate CYP3A4 inhibitor, the maximum dose is 25 mg once per night.2 Additionally, daridorexant should not be used in combination with strong or moderate CYP3A4 inducers.2
Patients with moderate liver impairment should not exceed a dose of 25 mg once per night, and patients with severe liver impairment should not take daridorexant.2
What Are the Adverse Effects?
The most common adverse effects are headache, fatigue, dizziness, and nausea.2
Are There Any Contraindications?
Daridorexant is contraindicated in patients with narcolepsy.2
What Are the Warnings and Precautions?
Other Counseling Tips: